Literature DB >> 22154540

A family with hyponatremia and the nephrogenic syndrome of inappropriate antidiuresis.

Detlef Bockenhauer1, Michael D Penney, David Hampton, William van't Hoff, Ambrose Gullett, Sankar Sailesh, Daniel G Bichet.   

Abstract

Nephrogenic syndrome of inappropriate antidiuresis (NSIAD) is an X-linked disorder caused by activating mutations in arginine vasopressin receptor 2 (AVPR2), resulting in persistently concentrated urine. We report on a family affected by NSIAD with the known mutation R137C, an arginine to cysteine substitution at amino acid 137. The spectrum of symptoms varied markedly and ranged from infrequent voiding to incidentally noted hyponatremia to recurrent admissions with hyponatremic seizures. There was evidence for physiologic compensatory mechanisms: most affected members intuitively compensated for the concentrated urine by curtailing their fluid intake. Before the genetic diagnosis, these members had recognized each other by their infrequent voiding, which especially suited one patient, a London cab driver. Interestingly, after water deprivation, urine osmolality was significantly lower in patients compared with unaffected members, suggesting desensitization of the downstream signaling pathway with persistent AVPR2 activation. Urine osmolality was as low as 241 mOsm/kg (241 mmol/kg) in patients, which could obfuscate the diagnosis. The development of symptoms of hyponatremia was strikingly different in the 2 male patients: one patient was asymptomatic with a plasma sodium level of 120 mEq/L (120 mmol/L), whereas another experienced seizures with similar values. Investigations of such genetically defined patients show clues for the understanding of human physiology and inform diagnosis and clinical management. Copyright Â
© 2012 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22154540     DOI: 10.1053/j.ajkd.2011.09.026

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  7 in total

1.  American Society of Nephrology Quiz and Questionnaire 2015: Electrolytes and Acid-Base Disorders.

Authors:  Mitchell H Rosner; Mark A Perazella; Michael J Choi
Journal:  Clin J Am Soc Nephrol       Date:  2016-01-29       Impact factor: 8.237

2.  GNAS: A New Nephrogenic Cause of Inappropriate Antidiuresis.

Authors:  Daniel G Bichet; Sébastien Granier; Detlef Bockenhauer
Journal:  J Am Soc Nephrol       Date:  2019-04-08       Impact factor: 10.121

Review 3.  The long-term complications of the inherited tubulopathies: an adult perspective.

Authors:  Maryam Khosravi; Stephen B Walsh
Journal:  Pediatr Nephrol       Date:  2014-02-25       Impact factor: 3.714

Review 4.  Focus on neonatal and infantile onset of nephrogenic syndrome of inappropriate antidiuresis: 12 years later.

Authors:  Flaminia Bardanzellu; Maria Cristina Pintus; Valentina Masile; Vassilios Fanos; Maria Antonietta Marcialis
Journal:  Pediatr Nephrol       Date:  2018-03-15       Impact factor: 3.714

Review 5.  Inherited Tubulopathies of the Kidney: Insights from Genetics.

Authors:  Mallory L Downie; Sergio C Lopez Garcia; Robert Kleta; Detlef Bockenhauer
Journal:  Clin J Am Soc Nephrol       Date:  2020-04-01       Impact factor: 8.237

6.  Adult female with symptomatic AVPR2-related nephrogenic syndrome of inappropriate antidiuresis (NSIAD).

Authors:  Jennifer Hague; Ruth Casey; Jonathan Bruty; Tom Legerton; Stephen Abbs; Susan Oddy; Andrew S Powlson; Mohamed Majeed; Mark Gurnell; Soo-Mi Park; Helen Simpson
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-02-09

7.  Integrin Beta 1 Is Crucial for Urinary Concentrating Ability and Renal Medulla Architecture in Adult Mice.

Authors:  Anna Iervolino; Luigi R De La Motte; Federica Petrillo; Federica Prosperi; Francesca Maria Alvino; Guglielmo Schiano; Alessandra F Perna; Danilo Di Matteo; Mario De Felice; Giovambattista Capasso; Francesco Trepiccione
Journal:  Front Physiol       Date:  2018-09-13       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.